Literature DB >> 22301141

HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Tommy Tong1, Ema T Crooks, Keiko Osawa, James M Binley.   

Abstract

Hypothetically, since native HIV-1 Env trimers are exclusively recognized by neutralizing antibodies, they might induce the neutralizing antibodies in a vaccine setting. This idea has not been evaluated due to the difficulty of separating trimers from nonfunctional Env (uncleaved gp160 and gp41 stumps). The latter are immunodominant and induce nonneutralizing antibodies. We previously showed that nonfunctional Env can be selectively cleared from virus-like particle (VLP) surfaces by enzyme digests (E. T. Crooks, T. Tong(,) K. Osawa, and J. M. Binley, J.Virol. 85:5825, 2011). Here, we investigated the effects of these digests on the antigenicity of VLPs and their sensitivity to neutralization. Before digestion, WT VLPs (bearing wild-type Env) and UNC VLPs (bearing uncleaved gp160) were recognized by various Env-specific monoclonal antibodies (MAbs), irrespective of their neutralizing activity, a result which is consistent with the presence of nonfunctional Env. After digestion, only neutralizing MAbs recognized WT VLPs, consistent with selective removal of nonfunctional Env (i.e., "trimer VLPs"). Digests eliminated the binding of all MAbs to UNC VLPs, again consistent with removal of nonfunctional Env. An exception was MAb 2F5, which weakly bound to digested UNC VLPs and bald VLPs (bearing no Env), perhaps due to lipid cross-reactivity. Trimer VLPs were infectious, and their neutralization sensitivity was largely comparable to that of undigested WT VLPs. However, they were ∼100-fold more sensitive to the MAbs 4E10 and Z13e1, suggesting increased exposure of the gp41 base. Importantly, a scatterplot analysis revealed a strong correlation between MAb binding and neutralization of trimer VLPs. This suggests that trimer VLPs bear essentially pure native trimer that should allow its unfettered evaluation in a vaccine setting.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22301141      PMCID: PMC3302546          DOI: 10.1128/JVI.06938-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.

Authors:  T Murakami; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Immunogenicity of full length and truncated SIV envelope proteins.

Authors:  A N Vzorov; D Lea-Fox; R W Compans
Journal:  Viral Immunol       Date:  1999       Impact factor: 2.257

3.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines.

Authors:  Jason Hammonds; Xuemin Chen; Xiugen Zhang; Francis Lee; Paul Spearman
Journal:  Vaccine       Date:  2007-09-25       Impact factor: 3.641

Review 5.  Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.

Authors:  S Phogat; R T Wyatt; G B Karlsson Hedestam
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

6.  Resistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases.

Authors:  R E Means; R C Desrosiers
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization.

Authors:  Emma T Crooks; Pengfei Jiang; Michael Franti; Sharon Wong; Michael B Zwick; James A Hoxie; James E Robinson; Penny L Moore; James M Binley
Journal:  Virology       Date:  2008-06-09       Impact factor: 3.616

8.  Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination.

Authors:  Michael Vaine; Shixia Wang; Emma T Crooks; Pengfei Jiang; David C Montefiori; James Binley; Shan Lu
Journal:  J Virol       Date:  2008-05-21       Impact factor: 5.103

9.  HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.

Authors:  Zhen-Yu J Sun; Kyoung Joon Oh; Mikyung Kim; Jessica Yu; Vladimir Brusic; Likai Song; Zhisong Qiao; Jia-huai Wang; Gerhard Wagner; Ellis L Reinherz
Journal:  Immunity       Date:  2008-01       Impact factor: 31.745

10.  A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

Authors:  Emma T Crooks; Penny L Moore; Michael Franti; Charmagne S Cayanan; Ping Zhu; Pengfei Jiang; Robbert P de Vries; Cheryl Wiley; Irina Zharkikh; Norbert Schülke; Kenneth H Roux; David C Montefiori; Dennis R Burton; James M Binley
Journal:  Virology       Date:  2007-06-19       Impact factor: 3.616

View more
  64 in total

Review 1.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

Review 2.  Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.

Authors:  Ivelin S Georgiev; M Gordon Joyce; Tongqing Zhou; Peter D Kwong
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

3.  Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.

Authors:  Ema T Crooks; Keiko Osawa; Tommy Tong; Samantha L Grimley; Yang D Dai; Robert G Whalen; Daniel W Kulp; Sergey Menis; William R Schief; James M Binley
Journal:  Virology       Date:  2017-03-06       Impact factor: 3.616

4.  Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.

Authors:  Evan M Cale; Jason Gorman; Nathan A Radakovich; Ema T Crooks; Keiko Osawa; Tommy Tong; Jiaqi Li; Raju Nagarajan; Gabriel Ozorowski; David R Ambrozak; Mangai Asokan; Robert T Bailer; Anthony K Bennici; Xuejun Chen; Nicole A Doria-Rose; Aliaksandr Druz; Yu Feng; M Gordon Joyce; Mark K Louder; Sijy O'Dell; Courtney Oliver; Marie Pancera; Mark Connors; Thomas J Hope; Thomas B Kepler; Richard T Wyatt; Andrew B Ward; Ivelin S Georgiev; Peter D Kwong; John R Mascola; James M Binley
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

Review 5.  Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.

Authors:  Weizao Chen; Tianlei Ying; Dimiter S Dimitrov
Journal:  Expert Opin Biol Ther       Date:  2013-01-07       Impact factor: 4.388

6.  Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James E Robinson; Mary Barnes; Cristian Apetrei; James M Binley
Journal:  Virology       Date:  2014-05       Impact factor: 3.616

Review 7.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

Review 8.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

Review 9.  Vaccine design: emerging concepts and renewed optimism.

Authors:  Sebastian K Grimm; Margaret E Ackerman
Journal:  Curr Opin Biotechnol       Date:  2013-03-07       Impact factor: 9.740

10.  Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency.

Authors:  Hillel Haim; Ignacio Salas; Kathleen McGee; Noah Eichelberger; Elizabeth Winter; Beatriz Pacheco; Joseph Sodroski
Journal:  Cell Host Microbe       Date:  2013-11-13       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.